About Genentech
What Genentech is building
Technologies used at Genentech
AWS 
Java
PostgreSQL
Git
Python Company culture
Putting Patients First
Improving patients' lives is what we strive to do. Each of our 13,500+ employees, from scientists to marketers, advances our mission.
Giving Back
We're passionate about applying our skills, time and resources to positively impact the patients we serve, the scientific community and the places where we live and work.
Funding rounds
Last funding round type
Company type
Genentech news and updates
Genentech launched Double Take on Sep 1st 22'.
In September, as part of the runup to New York Fashion Week, Genentech launched a bespoke fashion show called Double Take to champion disability visibility and inclusion.
Dec 23, 2022 | themedicinemaker.comBiogen, Inc. partners with Genentech
Biogen’s collaboration with Genentech could pay off again in the form of US royalties for the potential blood cancer drug glofitamab, a CD20xCD3 bispecific.
Dec 18, 2022 | sfbn.orgGenentech is developing anti-Aβ and anti-tau antibodies using AC Immune
At the same time, Genentech is developing anti-Aβ and anti-tau antibodies using AC Immune ’s proprietary SupraAntigen technology platform.
Nov 26, 2022 | pharmaceutical-technology.comGenentech had issues with recall of the ranibizumab injection on Oct 27th 22'.
This month, Genentech announced a voluntary recall of the ranibizumab injection (SUSVIMO) ocular implant and associated insertion tool.
Oct 27, 2022 | jdsupra.comArsenalBio partners with Genentech
ArsenalBio, a programmable immune cell therapy company based in South San Francisco, CA, has announced a multi-year collaboration with Genentech (a member of the Roche Group), also based in South San Francisco.
Oct 11, 2022 | kaloramainformation.comMaltzman left Genentech as Franchise Head, Vice President and Global Head of Gastrointestinal on Sep 10th 22'.
Dr. Maltzman joins IconOVir from Genentech, where she most recently served as Franchise Head, Vice President and Global Head of Gastrointestinal (GI) and Cancer Immunotherapy.
Oct 10, 2022 | businesswire.comGenentech is developing next-generation T cell therapies for solid tumors
Genentech has agreed to a multi-year collaboration with Arsenal Biosciences Inc. to develop next-generation T cell therapies for solid tumors.
Oct 5, 2022 | pharmant.comGenentech partnered with Boehringer Ingelheim GmbH on Jan 1st 83'.
In 1983, Genentech entered into a co-promotion agreement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding the commercialization of human tissue-type plasminogen activator (t-PA) 1.
Sep 4, 2022 | gene.comGenentech invests into assets : innovative biologics facility in the amount of $250M in California, United States
Genentech has invested more than $250 million in this innovative biologics facility, which is the latest example of its long-standing commitment to its California operations as well as its dedication to environmentally responsible manufacturing practices.
Aug 19, 2022 | gene.comGenentech launched Two Scientists Walk into a Bar on Jan 1st 16'.
Amgen is one of a long list of pharma companies that have launched their own podcasts since Genentech rolled out the industry’s first with its “Two Scientists Walk into a Bar'' back in 2016.
Jul 7, 2022 | fiercepharma.comGenentech launches list of five real estate trends
While no one knows what the future has in store, here Contact CENTURY 21 The Gene Group has compiled a list of five real estate trends that home buyers and sellers should be aware of as they navigate the market this year.
Mar 16, 2022 | c21thegenegroup.comGenentech launches Vabysmo
In a recent press release, Genentech announced approval of Vabysmo ™ (faricimab-svoa), a new advancement in the treatment approach for Wet Age-Related Macular Degeneration (AMD) and diabetic macular edema (DME).
Feb 3, 2022 | wolfeeyeclinic.comKaren Walker will leave Genentech as senior advisor on Sep 1st 22'.
Chief Medical Officer James Chung was hired last April from Amgen Inc. with deep experience in autoimmunity and innovative trial design, and Chief Technology Officer Karen Walker joined in September from Genentech Inc., where she was senior advisor for cell and gene therapy manufacturing.
Jan 1, 2022 | bizjournals.comConvelotx partnered with Genentech on Feb 11th 22'.
Dr. Tesar co-founded a Cleveland-based biotechnology company, Convelo Therapeutics, now partnered with Genentech, to advance new therapies from the laboratory into clinical testing to better the lives of patients and their families.
Jan 1, 2022 | biomedalliance.orgGenentech partners with Sloan Foundation
Genentech has awarded additional funding and is partnering with the Sloan Foundation to earmark $200,000 for “Priming the STEM Ph.D. pathway: Equity-centered faculty as key stakeholders in BIPOC graduate student success initiatives.”
Jan 1, 2022 | newswise.comGenentech launches updated interim data from the RAINBOWFISH study in pre-symptomatic babies
Genentech also announced updated interim data from the RAINBOWFISH study in pre-symptomatic babies with SMA under two months of age.
Jan 1, 2022 | businesswire.comGenentech has issues with conspiring to steal trade secrets
Two co-founders of a Taiwan-based biotechnology firm were handed prison sentences on Tuesday (March 15) for conspiring to steal trade secrets from Genentech.
Jan 1, 2022 | taiwannews.com.twGenentech launched Pinseeker’ on Mar 15th 22'.
Last week, Gene on Earth released single ‘Pinseeker’ from the forthcoming album.
Jan 1, 2022 | mixmag.netMiller left Genentech as Executive Director and Head of Product Development Excellence, Portfolio and Product Development Strategy on Feb 23rd 22'.
Miller comes to Totus from Genentech, where she was most recently Executive Director and Head of Product Development Excellence, Portfolio and Product Development Strategy.
Jan 1, 2022 | wivb.comGenentech had issues with patent infringement lawsuit on Mar 24th 22'.
Genentech unveiled its patent infringement lawsuit in early 2019.
Jan 1, 2022 | fiercepharma.comGenentech launches Phase 3 SKYSCRAPER-02 study
Genentech unit announced the Phase 3 SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq and chemotherapy as an initial treatment for people with extensive-stage small cell lung cancer did not meet its co-primary endpoint of progression-free survival.
Jan 1, 2022 | benzinga.comGenentech launched Ocrevus data on Apr 4th 22'.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new Ocrevus ® (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS).
Jan 1, 2022 | businesswire.comGenentech launches Elevatum trial of Vabysmo
Genentech launched the Elevatum trial of Vabysmo in patients with diabetic macular edema (DME) who come from underrepresented patient populations.
Jan 1, 2022 | ophthalmologymanagement.comGenentech partners with Thebonnellfoundation
However, in the United States, there are more than 3,000 Latinos living with CF. They frequently face healthcare disparities and misdiagnosis for “not fitting the mold” of a typical person with CF. 1 To make CFfamilia.com possible, Genentech partnered with The Bonnell Foundation, a CF advocacy group, which offers emotional and financial support, as well as tools to navigate the difficulties of living with CF. It also connects families with resources throughout their CF journey.
Jan 1, 2022 | gene.comGenentech invested into South San Francisco Unified School District in $32.5M on Jan 1st 15'.
Genentech and the Genentech Foundation have also invested $32.5m and 65,000+ volunteer hours in science education in the South San Francisco Unified School District since 2015.
Jan 1, 2022 | outsourcing-pharma.comGenentech filed suit against Tanvex Biopharma USA, Inc on Jun 2nd 22'.
Genentech filed a complaint yesterday against Tanvex in the U.S. District Court for the Southern District of California, alleging infringement of three patents under the BPCIA based on Tanvex’s submission of an aBLA for TX05, a proposed biosimilar of HERCEPTIN (trastuzumab).
Jan 1, 2022 | lexology.comGenentech invests into Atlanta University Center, Inc. in $500K
The Atlanta University Center Consortium was awarded a $500,000 grant from Genentech to address the underrepresentation of Black students pursuing graduate degrees in engineering.
Jan 1, 2022 | aucenter.eduGenentech launches CF hub website specifically for Latino families, patients and caregivers
Working with the Bonnell Foundation, Genentech created a CF hub website specifically for Latino families, patients and caregivers.
Jan 1, 2022 | endpts.comGenentech launches dedicated study in Graduation program for gantenerumab
At the Alzheimer's Association International Conference, Genentech announced a dedicated study in its Graduation program for gantenerumab that will aim to enroll a more diverse population.
Jan 1, 2022 | fiercebiotech.comGenentech partners with Jemincare
Roche subsidiary Genentech has inked a licensing deal with China-based Jemincare, gaining worldwide rights to develop and commercialize the company’s investigational androgen receptor degrader JMKX002992.
Jan 1, 2022 | fdanews.comFlywheel Partners with Roche and Genentech to Accelerate Development of Personalized Healthcare Solutions
Flywheel, the leading cloud-scale informatics platform for biomedical research and collaboration, announced today the successful integration of its platform by Roche and Genentech, Inc., a member of the Roche Group, for ingestion, classification, standardization, curation and analysis of medical imaging data.
Nov 22, 2021 | BioSpacePeninsula brain drug company snags Genentech vet as president
Sara Kenkare-Mitra received a $500,000 sign-on bonus as the company pushes its Alzheimer's and frontotemporal dementia drugs deeper into clinical trials.
Nov 16, 2021 | THE BUSINESS JOURNALSBicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics Limited (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech , a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies.
Oct 26, 2021 | BioSpaceGlobeNewswire, Inc. partners with Genentech
The Company announced a strategic collaboration with Genentech to research, develop, and commercialize allogeneic T-cell therapies.
Jan 1, 2021 | adaptimmune.comWendy Young left Genentech as Executive Partner on Aug 1st 21'.
Wendy Young joins MPM Capital as Executive Partner, having spent 25 years in biopharma, and most recently 15 years at Genentech, where she led small-molecule drug discovery.
Jan 1, 2021 | occam-global.comTania Mijas at Genentech receives award Fleet LatAm Manager of the Year Award
Tania Mijas, Senior Category Lead Travel, Fleet, Congresses, Meetings and Events for the Americas at Hoffmann La Roche - Genentech has been announced the winner of the first-ever Fleet LatAm Manager of the Year Award.
Jan 1, 2021 | globalfleet.comGarren leaves Genentech as Vice President, Global Head of Neuroimmunology
Garren joins Prothena from Genentech, where he served as Vice President, Global Head of Neuroimmunology.
Jan 1, 2021 | biospace.comKenkare-Mitra leaves Genentech as Senior Vice President, Development Sciences
Dr. Kenkare-Mitra joins Alector from Genentech where, as Senior Vice President, Development Sciences, she served as a member of the research and development leadership team, overseeing the transition of molecules from discovery to the clinic and their continued translation into medicines through clinical development.
Jan 1, 2021 | globenewswire.comEvotec AG partners with Genentech
Evotec AG (FSE:EVT) has entered into a ‘multi-year integrated drug discovery alliance’ with Genentech, a subsidiary of Roche Group (SWX:RO, SIX:ROG, PINK:RHHBY), to discover novel small molecule therapeutics.
Jan 1, 2021 | proactiveinvestors.co.ukGenentech hires Charles S. Fuchs as senior vice president and global head of product development for oncology and hematology
Charles S. Fuchs, director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital, has been named senior vice president and global head of product development for oncology and hematology at Roche and Genentech.
Jan 1, 2021 | cancerletter.comPieris Pharmaceuticals, Inc. partnered with Genentech on May 2nd 21'.
Avise Analytics take a look at some of them below: Pieris Pharmaceuticals recently entered into a multi-program research collaboration and license agreement with Genentech, to develop and commercialize respiratory and ophthalmology therapies, using Pieris’ proprietary Anticalin® technology.
Jan 1, 2021 | aviseanalytics.comGenentech partners with Novome Biotechnologies, Inc.
Genentech, a subsidiary of Roche, has joined forces with Novome Biotechnologies to develop targets against inflammatory bowel disease (IBD).
Jan 1, 2021 | ns-healthcare.comGenentech partners with Ribometrix, Inc.
Genentech will collaborate with Ribometrix to discover and develop small molecules that target 3-D structures in RNA.
Jan 1, 2021 | acs.orgKazia Therapeutics Limited partnered with Genentech on Oct 1st 16'.
Kazia entered into a worldwide exclusive license agreement with Genentech in October 2016.
Jan 1, 2021 | globenewswire.comRecursion partners with Genentech
Recursion is set to collaborate with Roche and Genentech in the fields of neuroscience and oncology to advance new medicines for patients using large-scale machine-learning and high-content screening (HCS) methods to map complex biology.
Jan 1, 2021 | scienceboard.netFlywheelarts partners with Genentech
Flywheel, the leading cloud-scale informatics platform for biomedical research and collaboration, announces a partnership with Roche and Genentech.
Jan 1, 2021 | businesswire.comNational Association of Emergency Medical Technicians partners with Genentech
The National Association of EMTs, in partnership with Genentech, is announcing a new public service announcement campaign about the signs and symptoms of stroke, and the importance of calling 911 once symptoms are recognized.
Jan 1, 2021 | ems1.comCell Cure Neurosciences LTD. partners with Genentech
(RTTNews) - Lineage Cell Therapeutics, Inc. (LCTX) said the company and its unit, Cell Cure Neurosciences, have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, for the development and commercialization of a retinal pigment epithelium cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration with geographic atrophy.
Jan 1, 2021 | nasdaq.comBlack Health Matters partnered with Genentech on Oct 9th 21'.
#BlackHealthMatters On Saturday, October 9 th, 2021, from 9 am – 5 pm Eastern, Black Health Matters will partner with Genentech, a member of the Roche Group, to host a virtual health fair, The Building the Bridge Virtual Summit: Closing the Health Literacy Gap.
Jan 1, 2021 | prnewswire.comPearceip partners with Genentech
“Pearceip is proud to partner with Genentech, given their commitment to patients and science in the cancer immunology field.
Jan 1, 2021 | globenewswire.comLifelink Systems Inc partnered with Genentech on Oct 4th 21'.
Lifelink Systems today announced a strategic collaboration with Genentech to provide a suite of advanced conversational technology solutions that will support a broad range of patient experience initiatives at the biotechnology leader.
Jan 1, 2021 | newenterpriseventures.comLifelink Systems Inc partnered with Genentech on Oct 4th 21'.
Lifelink Systems today announced a strategic collaboration with Genentech to provide a suite of advanced conversational technology solutions that will support a broad range of patient experience initiatives at the biotechnology leader.
Jan 1, 2021 | newenterpriseventures.comGenentech had issues with theft of trade secrets on Jul 7th 21'.
A former principal scientist at Genentech, the South San Francisco-based biotech corporation, has pleaded guilty with her husband in federal court to conspiracy and other charges related to the theft of trade secrets from the company.
Jan 1, 2021 | nbcbayarea.comGenentech is developing AIDS vaccine
In the 1990s Mike Powell was a senior scientist at Genentech working on developing an AIDS vaccine.
Jan 1, 2021 | fripp.comGenentech decreased headcount by 52 on Jan 4th 21'.
Genentech Inc. will cut 52 jobs Jan. 4 as part of an efficiency push by its Swiss parent Roche AG to concentrate on product development jobs with a direct line to potential drugs.
Jan 1, 2021 | bizjournals.comGenentech decreases headcount by 470
The job cuts come nearly a year after Genentech eliminated 470 jobs and as Roche faces increasing competition from so-called biosimilars.
Jan 1, 2021 | bizjournals.comGenentech had issues with alleged US patent infringement related to FKB238 on Apr 1st 21'.
In April 2021, Centus reached a settlement with Genentech over alleged US patent infringement related to FKB238.
Jan 1, 2021 | centerforbiosimilars.comGenentech is developing Bicycle -based immunotherapies
Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle -based immunotherapies against multiple targets.
Jan 1, 2021 | businesswire.comGenentech is developing cancer treatments
Adapatimmune has announced a partnership with Roche’s Genentech that will combine their expertise in cell therapy to develop new cancer treatments.
Jan 1, 2021 | pmlive.comGenentech is developing respiratory and ophthalmology therapies on Sep 11th 21'.
Strengths Pieris Pharmaceuticals recently entered into a multi-program research collaboration and license agreement with Genentech, to develop and commercialize respiratory and ophthalmology therapies, using Pieris’ proprietary Anticalin® technology.
Jan 1, 2021 | aviseanalytics.comPartnership for Health Analytic Research, LLC partners with Genentech
In collaboration with Genentech, PHAR published their analysis of Medicare FFS claims data examining healthcare utilization and costs in a US Medicare population diagnosed with Huntington’s disease (HD).
Jan 1, 2021 | pharllc.comPivot Interiors, Inc. partnered with Genentech on Jan 1st 02'.
Since 2002, Pivot has partnered with Genentech on countless projects including extensive work supporting new and updated buildings on the South San Francisco campus, as well as several additional locations.
Jan 1, 2021 | pivotinteriors.comLineage Cell Therapeutics, Inc. will partner with Genentech on Dec 1st 22'.
Lineage Cell Therapeutics (NYSEAMERICAN: LCTX ) stock is jumping more than 11% after announcing an exclusive worldwide collaboration with Genentech.
Jan 1, 2021 | nasdaq.comGenentech hired Eisner as senior vice president and global head of product development immunology on Jan 1st 10'.
Eisner joined Genentech in 2010 and recently was senior vice president and global head of product development immunology, infectious disease and ophthalmology, which included clinical development of drugs for respiratory, rheumatology and eye diseases and inflammatory bowel disease.
Jan 1, 2020 | bizjournals.comVarney retired from Genentech on Jul 1st 20'.
Dr. Varney retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies.
Jan 1, 2020 | erasca.comGenentech partners with Genentech
Lifelink Systems and Genentech to Collaborate on Advanced Conversational Patient Experience Platform Lifelink Systems ( @lifelnksystems) announced a strategic collaboration with Genentech to provide a suite of advanced conversational technology solutions that will support a broad range of patient experience initiatives at the biotechnology company.
Jan 1, 2020 | healthitanswers.netRelay Therapeutics Inc. partnered with Genentech on Dec 14th 20'.
Cambridge, Mass.-based Relay Therapeutics Inc. has signed a lucrative worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of its compound, RLY-1971, a potent inhibitor of SHP2 that is being investigated in a phase I dose-escalation study in patients with advanced or metastatic solid tumors.
Jan 1, 2020 | bioworld.comGenesis Therapeutics partnered with Genentech on Nov 2nd 20'.
Most recently, Genesis announced a multi-target partnership with Genentech.
Jan 1, 2020 | businesswire.comGenentech is developing RLY-1971
Genentech will develop RLY-1971 with the hope of expanding it into multiple combination studies, including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036.
Jan 1, 2020 | biopharminternational.comAC Immune partnered with Genentech on Jan 1st 17'.
Meanwhile, AC Immune, which specializes in treatment discovery, has developed 12 potential therapeutic and diagnostic products, and is currently collaborating with Genentech, Janssen Pharmaceuticals, and Eli Lilly and Company on other projects.
Jan 1, 2019 | alsnewstoday.comKineta, Inc. partners with Genentech
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Jan 1, 2018 | seattletimes.comGerber Products Company acquires Genentech
Gerber laid another cornerstone for continued success by gradually acquiring Genentech, then the largest U.S. biotech company focused on antibody drugs.
Jan 1, 2018 | sccij.jpGenentech partnered with GNS Healthcare, Inc. on Jun 1st 17'.
In June 2017, Genentech announced a research partnership with GNS Healthcare to identify and validate novel cancer drug targets using the company's proprietary REFS casual machine learning and simulation AI platform.
Jan 1, 2018 | biopharmatrend.comGenentech hired Gary Wilson on Jun 21st 18'.
Gary Wilson will be joining Genentech’s Biochemical and Cellular Pharmacology – Large Molecule department this summer to partake in an industrial internship.
Jan 1, 2018 | coonlabs.comGenentech had issues with criminal theft for conspiring to steal trade secrets on Oct 1st 18'.
In late October 2018, former Genentech employees were charged with criminal theft for conspiring to steal trade secrets to assist biosimilar developer JHL Biotech in the development of its products.
Jan 1, 2018 | centerforbiosimilars.comRoche merged with Genentech on Jan 1st 09'.
Similarly, Dragonfly and Merck have announced a new business deal for about $700 million just a week after Roche and Genentech merger.
Jan 1, 2018 | mmjobserver.comCelltrion Group partners with Genentech
Teva and Celltrion have reached a settlement agreement with Genentech, including entry terms.
Jan 1, 2018 | globalbankingandfinance.comGenentech is developing quantitative imaging diagnostics for lung diseases
Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.
Jan 1, 2017 | imbio.comCarmot Therapeutics, Inc. partnered with Genentech on Jul 6th 16'.
Carmot Therapeutics announced today that it has entered into a drug discovery collaboration and license agreement with Genentech, a member of the Roche Group.
Jan 1, 2016 | carmot-therapeutics.usGenentech partners with American Cancer Society
Genentech, which markets the $3 billion a year lung cancer immunotherapy Tecentriq and is Roche's oncology powerhouse, teamed with the American Cancer Society, American Lung Association and other health organizations on the PSA and the larger “Screen Your Lungs” awareness campaign, which debuted in 2021 and is continuing this year.
Jan 1, 2016 | fiercepharma.comStanford University partners with Genentech
A team of researchers from Stanford University working with biotechnology corporation Genentech, has developed an artificial-intelligence based system that can safely add clinical trial participants that may have previously been excluded.
Jan 1, 2016 | medicalxpress.comGenentech invests into assets : manufacturing facility
This included Genentech’s build of a US$140 million commercial-scale manufacturing facility and GlaxoSmithKline (GSK) construction of a US$200 million commercial-scale manufacturing facility to produce paediatric vaccines [2].
Jan 1, 2016 | greyrigge.comGenentech is developing HM95573
Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commercialize HM95573.
Jan 1, 2016 | businesswire.comGenentech is developing mRNA-based cancer therapies
images-2Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies.
Jan 1, 2016 | awawa.org